Zuranolone

Indications

• FDA-approved in August 2023 for the treatment of postpartum depression in adults, as a discrete 14-day oral course.
• The pivotal trials enrolled women with severe postpartum depression whose symptoms began in the third trimester or within 4 weeks of delivery.
• Not approved for major depressive disorder outside the postpartum period; the FDA issued a complete response letter for that indication.
• Improvement in depressive symptoms appeared by day 3 in trials and was maintained through day 45, well past the end of dosing.
• May be used alone or alongside an existing oral antidepressant, and it does not require an ongoing maintenance prescription.
• Safety and effectiveness in patients under 18 years of age have not been established for this indication.

Mechanism of action

• A synthetic analogue of allopregnanolone, the endogenous neuroactive steroid metabolite of progesterone that falls abruptly after delivery.
• Acts as a positive allosteric modulator at both synaptic and extrasynaptic GABA-A receptors, enhancing phasic and tonic inhibition.
• Extrasynaptic delta-subunit receptor modulation is the key difference from benzodiazepines, which act only at synaptic sites.
• Restoring GABAergic tone after the postpartum allopregnanolone withdrawal is the proposed basis for rapid symptom relief.
• The same GABA-A potentiation produces the sedation and driving impairment that dominate the safety profile of the drug.

Pharmacokinetics

• Peak plasma concentrations occur about 5 to 6 hours after dosing, and a fat-containing meal substantially increases absorption.
• Terminal half-life is roughly 19 to 23 hours, which supports once-daily evening dosing across the 14-day treatment course.
• Metabolized predominantly by CYP3A4, so strong inhibitors and inducers of that enzyme meaningfully alter exposure.
• Highly protein bound with negligible renal excretion of unchanged drug; elimination is largely as inactive metabolites.
• Exposure rises in severe hepatic impairment and in moderate to severe renal impairment, both of which require a lower dose.

Dosing

• Give 50 mg PO once daily in the evening for 14 days, taken with a fat-containing meal of roughly 400 to 1000 calories.
• Dose in the evening to align peak sedation with sleep, and instruct the patient not to drive for at least 12 hours after each dose.
• Reduce to 30 mg once daily if central nervous system depressant effects such as excessive sedation are problematic.
• Use 30 mg once daily in severe hepatic impairment and in moderate or severe renal impairment with eGFR below 60 mL/min/1.73 m2.
• Reduce to 30 mg once daily when a strong CYP3A4 inhibitor cannot be avoided, and avoid strong CYP3A4 inducers entirely.
• No taper is required because treatment is a fixed 14-day course; a repeat course may be given if symptoms recur.

Adverse effects

• Somnolence occurs in roughly 36 percent of patients and dizziness in about 13 percent, both concentrated in the first days of dosing.
• Sedation, fatigue, diarrhea, and headache are the other common adverse effects reported in the postpartum depression trials.
• Driving impairment is the central safety concern and patients frequently cannot recognize the degree of their own impairment.
• Additive central nervous system depression with alcohol, opioids, or benzodiazepines can produce profound sedation or respiratory risk.
• Suicidal thoughts and behavior have been reported, so depression severity must still be monitored throughout the 14-day course.
• Embryo-fetal toxicity was seen in animal studies, requiring effective contraception during and for 1 week after treatment.

Monitoring

• Confirm at each contact that the patient is not driving or operating machinery within 12 hours of a dose during the course.
• Assess depression severity and suicidality before starting, during the course, and again after day 15 when dosing has ended.
• Counsel women of reproductive potential to use effective contraception during treatment and for 1 week after the last dose.
• Verify renal and hepatic function before starting, since both severe hepatic and moderate renal impairment require 30 mg dosing.
• Review concurrent central nervous system depressants and CYP3A4 modulators before the first dose and at any dose change.

Interactions

• Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, and ritonavir raise exposure and require reduction to 30 mg daily.
• Strong or moderate CYP3A4 inducers including rifampin, carbamazepine, and St. John's wort reduce exposure and should be avoided.
• Alcohol, opioids, benzodiazepines, and sedating antihistamines produce additive sedation and increase the risk of accidental injury.
• Zuranolone can raise exposure to P-glycoprotein substrates with narrow therapeutic index, such as digoxin, so monitor closely.
• No monoamine oxidase inhibitor contraindication exists, but combined sedation with any central depressant is the main practical hazard.

Special populations

• Indicated specifically in postpartum women, though it may cause fetal harm and should not be used during an ongoing pregnancy.
• Zuranolone is present in human milk at low levels; a decision to continue breastfeeding should weigh benefit against infant sedation.
• Not established as safe or effective under 18 years, so adolescent postpartum patients require individualized risk discussion.
• Geriatric data are absent because the indication is postpartum, and no age-based dose adjustment has been defined.
• Use 30 mg daily in severe hepatic impairment and in moderate to severe renal impairment; no adjustment is needed for mild impairment.

Clinical pearls

• A 14-day course, not a maintenance drug; benefit persisted to day 45 after dosing stopped.
• Must be taken with a fatty meal in the evening; food materially raises absorption.
• No driving for 12 hours after each dose, and patients often misjudge their own impairment.